HT
VKTX icon

Headlands Technologies’s Viking Therapeutics VKTX Stock Holding History

Headlands Technologies’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$787K Sell
20,164
-28,982
-59% -$936K 0.08% 295
2026
Q1 		$1.6M Buy
49,146
+18,711
+61% +$601K 0.18% 114
2025
Q4 		$1.07M Buy
+30,435
New +$1.08M 0.09% 257

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Headlands Technologies's VKTX Position: Q2 2026 in Review

Headlands Technologies reduced its Viking Therapeutics (VKTX) stake by 59% in Q2 2026, selling an estimated $936K and leaving 20,164 shares worth $787K. The position accounts for 0.08% of the portfolio, ranked #295.

Headlands Technologies first reported a position in VKTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.6M in Q1 2026. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Headlands Technologies held 20,164 shares of Viking Therapeutics worth $787K as of Q2 2026.
  • Headlands Technologies sold 28,982 Viking Therapeutics shares in Q2 2026, an estimated $936K.
  • Viking Therapeutics made up 0.08% of Headlands Technologies's portfolio in Q2 2026, its #295 holding.
  • Headlands Technologies first reported a position in Viking Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Headlands Technologies's Viking Therapeutics position peaked at $1.6M in Q1 2026.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.